Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-Desmethylverapamil
- Development stage
- Phase 3
- Lead developer
- Knoll
- Modality
- Small Molecules
01
Overview
O-Desmethylverapamil (D702) is a primary active metabolite of verapamil, a non-dihydropyridine calcium channel blocker. Verapamil and its metabolites are used primarily in the management of cardiovascular conditions such as hypertension, angina pectoris, and certain arrhythmias. D702 is formed via hepatic metabolism (primarily CYP3A4/5) and retains pharmacological activity similar to the parent compound by inhibiting L-type calcium channels in cardiac and vascular smooth muscle cells. This action leads to decreased myocardial contractility and vasodilation[2][7].
- Other names
- O-DesmethylverapamilnorverapamilD-702D702D 702
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on O-Desmethylverapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on O-Desmethylverapamil.